Venetoclax with decitabine or azacitidine in relapsed or refractory acute myeloid leukemia
Ian Bouligny, Graeme Murray, Michael Doyel, Tilak Patel, Josh Boron, Valerie Tran, Juhi Gor, Yiwei Hang, Yanal Alnimer, Thuy Ho, Kyle Zacholski, Chad Venn, Nolan A. Wages, Steven Grant, Keri Maher
Topics & Concepts
VenetoclaxDecitabineAzacitidineMedicineOncologyHypomethylating agentInternal medicineMyeloid leukemiaCytarabineKRASRefractory (planetary science)LeukemiaChronic lymphocytic leukemiaDNA methylationCancerAstrobiologyChemistryGene expressionBiochemistryGeneColorectal cancerPhysicsAcute Myeloid Leukemia ResearchHistone Deacetylase Inhibitors ResearchMyeloproliferative Neoplasms: Diagnosis and Treatment